ULTOMIRIS Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ULTOMIRIS Growth

1. Long-Acting C5 Inhibition With Significant Convenience Advantage

Ultomiris is a long-acting complement C5 inhibitor engineered from eculizumab to provide sustained complement blockade with fewer infusions.

Key differentiation:

• Intravenous dosing once every 8 weeks, compared with every 2 weeks for earlier therapies.
• This extended dosing interval significantly reduces treatment burden and improves patient compliance.

The improved dosing schedule has encouraged physicians and patients to switch from older complement inhibitors, accelerating market penetration.

2. Rapid Conversion From Earlier Complement Therapy

A major growth driver for Ultomiris has been the conversion of patients from older therapies, particularly eculizumab.

Key adoption trends:

• Over 70% of PNH patients in major markets have transitioned to Ultomiris from its predecessor therapy.
• More than 60% of newly diagnosed PNH patients in Europe initiate therapy with Ultomiris.

This switching strategy allows AstraZeneca to maintain dominance in the complement inhibitor market while improving patient outcomes.

3. Expanding Regulatory Approvals Across Multiple Rare Diseases

Ultomiris has expanded beyond hematology into neurology and nephrology indications.

Major approved indications include:

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Generalized Myasthenia Gravis (gMG)
• Neuromyelitis Optica Spectrum Disorder (NMOSD)

In 2024, the U.S. FDA approved Ultomiris for NMOSD, making it the first long-acting C5 inhibitor for this condition.

The approval was based on the CHAMPION-NMOSD trial, which reported zero relapses among treated patients during a median 73-week follow-up.

This expanding label significantly increases the addressable patient population.

4. Growing Complement-Mediated Disease Market

Complement pathway disorders are increasingly recognized as key drivers of rare autoimmune diseases.

Key market trends:

• Rising diagnosis rates for PNH, aHUS, and neurological complement disorders.
• Improved clinical guidelines enabling earlier identification of eligible patients.

These trends are expanding the treatable population and sustaining demand for complement inhibitors like Ultomiris.

5. Strong Commercial Performance and Rapid Revenue Growth

Ultomiris has demonstrated robust commercial growth since launch.

Sales performance highlights:

• $1.03 billion in U.S. sales during the first half of 2024, representing 27% year-over-year growth.
• Ultomiris accounted for 21% of growth in the U.S. hematological disorders market in 2023.

ULTOMIRIS Recent Developments

Early Phase III data (ALXN1210-TMA-314) released in June 2025, showed ULTOMIRIS helped pediatric patients with thrombotic microangiopathy (TMA) after stem cell transplantation achieve an 87.2% survival rate.

"ULTOMIRIS Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ULTOMIRIS for approved indication like PNH, Haemolytic uraemic syndrome, Myasthenia gravis; as well as potential indications like Acute kidney injury, Delayed graft function, IgA nephropathy, Thrombotic microangiopathies in the 7MM. A detailed picture of ULTOMIRIS's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ULTOMIRIS for approved and potential indications. The ULTOMIRIS market report provides insights about ULTOMIRIS's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ULTOMIRIS performance, future market assessments inclusive of the ULTOMIRIS market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ULTOMIRIS sales forecasts, along with factors driving its market.

ULTOMIRIS Drug Summary

ULTOMIRIS (Ravulizumab) is a long-acting humanized monoclonal antibody complement C5 inhibitor developed by Alexion (AstraZeneca), administered via intravenous infusion, indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) in adults and pediatric patients one month of age and older to reduce hemolysis; atypical hemolytic uremic syndrome (aHUS) in patients one month and older to inhibit complement-mediated thrombotic microangiopathy (not for Shiga toxin E. coli-related HUS); generalized myasthenia gravis (gMG) in adults; and anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) in adults, by binding with high affinity to C5 to prevent its cleavage into pro-inflammatory C5a and lytic C5b-9 complex, offering sustained inhibition over 8-week dosing intervals compared to biweekly eculizumab. Engineered for extended half-life via modified Fc region, it rapidly achieves free C5 suppression (<0.5 mcg/mL) post-infusion, stabilizing hemoglobin, reducing transfusions, and improving fatigue in PNH while mitigating kidney damage in aHUS, though it carries a boxed warning for serious meningococcal infections requiring vaccination, REMS enrollment, and prior resolution of active infections. The report provides ULTOMIRIS's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ULTOMIRIS Market Report

The report provides insights into:

• A comprehensive product overview including the ULTOMIRIS MoA, description, dosage and administration, research and development activities in approved indications like PNH, Haemolytic uraemic syndrome, Myasthenia gravis; as well as potential indications like Acute kidney injury, Delayed graft function, IgA nephropathy, Thrombotic microangiopathies.
• Elaborated details on ULTOMIRIS regulatory milestones and other development activities have been provided in ULTOMIRIS market report.
• The report also highlights ULTOMIRIS's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ULTOMIRIS market report also covers the patents information, generic entry and impact on cost cut.
• The ULTOMIRIS market report contains current and forecasted ULTOMIRIS sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ULTOMIRIS market report also features the SWOT analysis with analyst views for ULTOMIRIS in approved and potential indications.

Methodology:

The ULTOMIRIS market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ULTOMIRIS Analytical Perspective by DelveInsight

• In-depth ULTOMIRIS Market Assessment

This ULTOMIRIS sales market forecast report provides a detailed market assessment of ULTOMIRIS for approved indication like PNH, Haemolytic uraemic syndrome, Myasthenia gravis; as well as potential indications like Acute kidney injury, Delayed graft function, IgA nephropathy, Thrombotic microangiopathies in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ULTOMIRIS sales data uptil 2034.

• ULTOMIRIS Clinical Assessment

The ULTOMIRIS market report provides the clinical trials information of ULTOMIRIS for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ULTOMIRIS Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ULTOMIRIS Market Potential & Revenue Forecast

• Projected market size for the ULTOMIRIS and its key indications
• Estimated ULTOMIRIS sales potential (ULTOMIRIS peak sales forecasts)
• ULTOMIRIS Pricing strategies and reimbursement landscape

ULTOMIRIS Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ULTOMIRIS Market positioning compared to existing treatments
• ULTOMIRIS Strengths & weaknesses relative to competitors

ULTOMIRIS Regulatory & Commercial Milestones

• ULTOMIRIS Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ULTOMIRIS Clinical Differentiation

• ULTOMIRIS Efficacy & safety advantages over existing drugs
• ULTOMIRIS Unique selling points

ULTOMIRIS Market Report Highlights

• In the coming years, the ULTOMIRIS market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ULTOMIRIS companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS's dominance.
• Other emerging products for PNH, Haemolytic uraemic syndrome, Myasthenia gravis; as well as potential indications like Acute kidney injury, Delayed graft function, IgA nephropathy, Thrombotic microangiopathies are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in approved and potential indications.
• Analyse ULTOMIRIS cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ULTOMIRIS sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ULTOMIRIS in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ULTOMIRIS? How strong is ULTOMIRIS's clinical and commercial performance?
• What is ULTOMIRIS's clinical trial status in each individual indications such as PNH, Haemolytic uraemic syndrome, Myasthenia gravis; as well as potential indications like Acute kidney injury, Delayed graft function, IgA nephropathy, Thrombotic microangiopathies and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ULTOMIRIS Manufacturers?
• What are the key designations that have been granted to ULTOMIRIS for approved and potential indications? How are they going to impact ULTOMIRIS's penetration in various geographies?
• What is the current and forecasted ULTOMIRIS market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ULTOMIRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ULTOMIRIS for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ULTOMIRIS? What is the duration of therapy and what are the geographical variations in cost per patient?